West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 16 15 2015 12 01 Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging 6765 6768 31493 EN Journal Article 1970 01 01 Aims: To study the effectiveness of human recombinant endostatin injection (Endostar®) combined withcisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CTperfusion imaging. <br/><b>Methods</b>: From April 2011 to September 2014, 76 patients with advanced NSCLC whowere treated with platinum-based doublets were divided into group A (36 patients) and group B (40 patients).Endostar® 15mg/day was administered 4 days before chemotherapy and combined with chemotherapy from day5 in group A, and combined with chemotherapy from the first day in Group B. Endostar® in the two groups wasinjected intravenously for 14 days. <br/><b>Results</b>: Treatment effectiveness in the two groups differed with statisticalsignificance (p<0.05). Effectiveness evaluated by CT perfusion imaging, BF, BV, MTT and PS also demonstratedsignificant differences (all p<0.05). Adverse reactions in the two groups did not significantly vary (p> 0.05).<br/><b>Conclusions</b>: The response rate with Endostar® administered 4 days before chemotherapy and combined withchemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the firstday, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes. https://journal.waocp.org/article_31493_d67cac1e94d99f984f5f89568b26e199.pdf